Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 75

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 75
---
 represent a significant asset and serve as the source of our technological and product innovations. If we
are unable to hire, train and retain such personnel in a timely manner, the development and introduction of our products could be delayed
and our ability to sell our products and otherwise to grow our business will be impaired and the delay and inability may have a detrimental
effect upon our performance.

Risks related to global public health concerns

Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.

Pandemics
or disease outbreaks, such as the COVID-19 pandemic, have created and may continue to create significant volatility, uncertainty and economic
disruption in the markets we operate in and may negatively impact business and healthcare activity globally. In response to the COVID-19
pandemic, governments around the world imposed measures designed to reduce the transmission of COVID-19 and individuals continue to respond
to the fear of contracting COVID-19. It is not possible to accurately predict the extent of the adverse effects of the pandemic on
our business. However, we have experienced certain impacts and may experience others which, if they continue for an extended period of
time, could have material adverse effects on our operations and the execution of our business plans. For example, we experienced some
delays in our clinical trials, in particular our Phase 1 trials of MTX110 in DMG at Columbia University and in medulloblastoma at the
University of Texas. Individuals defer seeking treatment, physicians have fewer in-person meetings to recruit and enroll patients, and
recruited patients are hindered by restrictions in traveling to and accessing clinical sites. In addition, resources at hospitals have
been diverted to dealing with the pandemic, causing delays in scheduling screening evaluations, implant procedures, and follow-up monitoring
visits. As a result of the foregoing factors, the expected timeline for data readouts of our clinical trials may be negatively impacted,
which would adversely affect our business.

| 38 |

The extent to which fear of exposure to or actual effects of COVID-19, new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the United States, United Kingdom and international healthcare systems, the United States, United Kingdom